# Demecan Holding

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/demecan-holding

- Industry: Healthcare
- Headquarters: Berlin, Germany
- Website: www.demecan.de
- Total disclosed funding: $23M
- Latest round: Series B (Dec 1, 2022)
- Investors on record: 9

## About

Based in Germany, Demecan Holding GmbH specializes in the cultivation and distribution of medical cannabis products, providing a range of pharmaceutical-grade solutions for patients and healthcare professionals across the country.Demecan Holding GmbH, founded in 2017 in Berlin, Germany, focuses on the medical cannabis market, primarily involved in the cultivation and distribution of cannabis-based pharmaceuticals. The company has successfully completed 4 funding deals, with the latest being a Series B round that raised EUR 15.000 mn on August 9, 2024. The company was co-founded by Constantin von der Groeben and Cornelius Maurer, who have experience in entrepreneurship, though specific details about their prior ventures are not available.Demecan specializes in the cultivation and distribution of medical cannabis products in Germany, offering cannabis extracts utilized in capsules and other medicinal formats. The company ensures its products meet safety standards and are accessible through a network of pharmacies, facilitating patient access to required medical cannabis treatments while adhering to stringent regulations.Demecan generates revenue through sales to pharmacies, which order its cannabis-based medicines directly, forming a B2B relationship tailored to patient prescriptions. The revenue model is designed to maintain a reliable supply chain, enabling pharmacies to meet patient needs efficiently.In August 2024, Demecan Holding GmbH secured additional funding from Trog Hawley Capital to enhance its growth and product line expansion. The company plans to introduce new products and expand its market presence, though specific new markets have not been disclosed. The recent funding will be utilized to support these initiatives, ensuring the company can continue developing its offerings in the medical cannabis sector.

## Funding rounds

- Series B, Dec 1, 2022, $16M — b2venture, Mittelstandische Beteiligungsgesellschaft Sachsen, Futury Capital, WB-Beteiligungs-GmbH & Co. KG, Enexis AB, Scope Hanson, ArteFin GmbH, Gizeh Raucherbedarf GmbH
- Series A, Sep 18, 2019, $7.7M — b2venture, Schadeberg Family Office

## Investors

- b2venture (https://capitalatlas.ai/funds/b2venture) — Series A, Series B
- Schadeberg Family Office — Series A
- Mittelstandische Beteiligungsgesellschaft Sachsen (https://capitalatlas.ai/funds/mittelstandische-beteiligungsgesellschaft-sachsen) — Series B
- Futury Capital (https://capitalatlas.ai/funds/futury-capital) — Series B
- WB-Beteiligungs-GmbH & Co. KG — Series B
- Enexis AB (https://capitalatlas.ai/funds/enexis-ab) — Series B
- Scope Hanson (https://capitalatlas.ai/funds/scope-hanson) — Series B
- ArteFin GmbH — Series B
- Gizeh Raucherbedarf GmbH — Series B